EBAC
European Biotech Acquisition Corp. [EBAC] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
EBAC Stock Summary
In the News
EBAC Financial details
Company Rating
Sell
Market Cap
183.5M
Income
3.5M
Revenue
0
Book val./share
9.5
Cash/share
0.02
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
-
P/E
40.74
Forward P/E
-
PEG
-7.61
P/S
-
P/B
1.18
P/C
559.5
P/FCF
-356.46
Quick Ratio
0.39
Current Ratio
0.45
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.2
EPS next Y
-
EPS next Q
-
EPS this Y
-37.21%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-561.07%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
3%
ROE
3%
ROC
-0.02%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.282-14.1
52W High
-20.07%
52W Low
+24.33%
RSI
-
Rel Volume
0.61
Avg Volume
127.6K
Volume
77.64K
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-4.44%
-
-
-
-
Beta
-
-
-
Volatility
0.23%, 0.23%
Prev Close
0%
Price
11.19
Change
0.9%
EBAC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2021-12-31 | 2022-12-31 |
|---|---|---|---|
| 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | |
| Net income per share | 0.11 | 0.27 | |
| Operating cash flow per share | -0.05 | -0.04 | |
| Free cash flow per share | -0.05 | -0.04 | |
| Cash per share | 0.06 | 0.02 | |
| Book value per share | 8.84 | 9.5 | |
| Tangible book value per share | 8.84 | 9.5 | |
| Share holders equity per share | 8.84 | 9.5 | |
| Interest debt per share | 0 | -0.25 | |
| Market cap | 132.41M | 128.82M | |
| Enterprise value | 131.54M | 128.51M | |
| P/E ratio | 89.55 | 36.77 | |
| Price to sales ratio | 0 | 0 | |
| POCF ratio | -192.22 | -250.24 | |
| PFCF ratio | -192.22 | -250.24 | |
| P/B Ratio | 1.1 | 1.06 | |
| PTB ratio | 1.1 | 1.06 | |
| EV to sales | 0 | 0 | |
| Enterprise value over EBITDA | -35.76 | -21.5 | |
| EV to operating cash flow | -190.96 | -249.64 | |
| EV to free cash flow | -190.96 | -249.64 | |
| Earnings yield | 0.01 | 0.03 | |
| Free cash flow yield | -0.01 | 0 | |
| Debt to equity | 0 | 0 | |
| Debt to assets | 0 | 0 | |
| Net debt to EBITDA | 0.24 | 0.05 | |
| Current ratio | 1.81 | 0.45 | |
| Interest coverage | 0 | 0.89 | |
| Income quality | -0.47 | -1.5 | |
| Dividend Yield | 0 | 0 | |
| Payout ratio | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | |
| Capex to revenue | 0 | 0 | |
| Capex to depreciation | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | |
| Graham number | 4.64 | 7.66 | |
| ROIC | -0.01 | -0.24 | |
| Return on tangible assets | 0.01 | 0.03 | |
| Graham Net | -0.49 | -0.65 | |
| Working capital | 411.27K | -438.93K | |
| Tangible asset value | 120.86M | 121.2M | |
| Net current asset value | -6.69M | -8.19M | |
| Invested capital | 0 | 0 | |
| Average receivables | 0 | 0 | |
| Average payables | 0 | 208.72K | |
| Average inventory | 0 | 0 | |
| Days sales outstanding | 0 | 0 | |
| Days payables outstanding | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | |
| Receivables turnover | 0 | 0 | |
| Payables turnover | 0 | 0 | |
| Inventory turnover | 0 | 0 | |
| ROE | 0.01 | 0.03 | |
| Capex per share | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
| Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | 0.12 | 0.2 | 0.05 | 0.01 | -0.06 | |
| Operating cash flow per share | 0.01 | -0.01 | -0.03 | 0 | 0.01 | |
| Free cash flow per share | 0.01 | -0.01 | -0.03 | 0 | 0.01 | |
| Cash per share | 0.05 | 0.04 | 0.02 | 0.02 | 0.02 | |
| Book value per share | -0.41 | 7.46 | 7.47 | 7.45 | 9.5 | |
| Tangible book value per share | 7.37 | 7.46 | 7.47 | 7.45 | 9.5 | |
| Share holders equity per share | -0.41 | 7.46 | 7.47 | 7.45 | 9.5 | |
| Interest debt per share | -0.08 | -0.11 | -0.03 | -0.04 | -0.02 | |
| Market cap | 158.9M | 159.72M | 160.54M | 162.51M | 128.82M | |
| Enterprise value | 158.03M | 159M | 160.23M | 162.24M | 128.51M | |
| P/E ratio | 19.45 | 12.16 | 51.87 | 188.76 | -41.81 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | 1.28K | -1.06K | -391.39 | -4.58K | 1.59K | |
| PFCF ratio | 1.28K | -1.06K | -391.39 | -4.58K | 1.59K | |
| P/B Ratio | -23.76 | 1.31 | 1.31 | 1.33 | 1.06 | |
| PTB ratio | -23.76 | 1.31 | 1.31 | 1.33 | 1.06 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 210.63 | -78.04 | -169.48 | -99.5 | -94.12 | |
| EV to operating cash flow | 1.27K | -1.06K | -390.64 | -4.57K | 1.59K | |
| EV to free cash flow | 1.27K | -1.06K | -390.64 | -4.57K | 1.59K | |
| Earnings yield | 0.01 | 0.02 | 0 | 0 | -0.01 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | -1.16 | 0.35 | 0.33 | 0.17 | 0.23 | |
| Current ratio | 1.81 | 1.79 | 1.11 | 0.28 | 0.45 | |
| Interest coverage | 0.42 | 0.15 | 0.65 | 1.65 | 5.88 | |
| Income quality | 0.17 | -0.1 | -2.04 | 0.09 | -0.08 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.07 | 5.8 | 2.82 | 1.48 | 3.59 | |
| ROIC | 0.22 | 0 | -0.01 | 0 | -0.01 | |
| Return on tangible assets | 0.02 | 0.03 | 0.01 | 0 | -0.01 | |
| Graham Net | -0.41 | -0.33 | -0.33 | -0.38 | -0.65 | |
| Working capital | 411.27K | 419.61K | 47.24K | -968.04K | -438.93K | |
| Tangible asset value | 120.86M | 122.37M | 122.57M | 122.17M | 121.2M | |
| Net current asset value | -6.69M | -5.2M | -5.17M | -6.14M | -8.19M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 28.95K | 218.49K | 255.18K | 172.05K | 286.18K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.31 | 0.03 | 0.01 | 0 | -0.01 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
EBAC Frequently Asked Questions
What is European Biotech Acquisition Corp. stock symbol ?
European Biotech Acquisition Corp. is a NL stock and trading under the symbol EBAC
What is European Biotech Acquisition Corp. stock quote today ?
European Biotech Acquisition Corp. stock price is $11.19 today.
Is European Biotech Acquisition Corp. stock public?
Yes, European Biotech Acquisition Corp. is a publicly traded company.
Company Profile
- Volume Average 127.6K
- Market Capitalization 183.5M
- CEO Mr. Eduardo Bravo Fernandez de Araoz
- Headquarters Amsterdam,NL
- IPO Date 2021-05-11
-
Website
https://www.lspvc.com/ebac 
European Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. European Biotech Acquisition Corp. was incorporated in 2021 and is based in Amsterdam, the Netherlands.
